Warby Parker reported Q3 revenue growth of 10.4% and adjusted EBITDA above guidance, narrowed 2026 revenue guidance to $966 to $976 million, and prepared to launch Intelligent Eyewear pre-orders on November 12th, with customer deliveries beginning mid-December.
WRBY · Warby Parker Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Warby Parker reported $722.7 million of net revenue, up $62.8 million or 9.5%, and $13.4 million of net income for the nine months ended September 30, 2026.
Warby Parker reported third-quarter revenue of $244.7 million, up 10.4%, net income of $5.6 million and Adjusted EBITDA of $28.6 million. It narrowed 2026 revenue guidance to $966 to $976 million and reaffirmed Adjusted EBITDA guidance of $117 to $119 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Warby Parker delivered 10.4% Q3 revenue growth, an adjusted EBITDA beat, gross-margin expansion, customer monetization gains, strong growth in exams, insurance and e-commerce, and continued store expansion. FY and Q4 guidance provides further growth, with Intelligent Eyewear expected to accelerate growth in 2027. The main risks are traffic and category softness, moderating active-customer growth, higher operating costs, lower net income, negative free cash flow and a limited Intelligent Eyewear contribution in 2026.
- + GAAP gross margin expanded to 54.4% from 54.1%, while adjusted gross margin rose to 54.6% from 54.2%. new
- + Active customers grew 3.0% to 2.74 million, while average revenue per customer increased 6.7% to $342. new
- + The company opened 12 stores in Q3 and 41 year to date and remains on track for 50 openings in 2026. new
- + Management expects Intelligent Eyewear to drive a rapid growth acceleration in 2027. new
- − Store traffic remained soft, industry eyewear unit growth weakened, and cash-pay consumers faced greater pressure. new
- − Adjusted SG&A increased to 49.4% of revenue from 48.7%, while GAAP SG&A increased by 50 basis points as a percentage of revenue. new
- − Q3 net income decreased $0.3 million to $5.6 million. new
- − Free cash flow was negative $2.0 million in Q3, affected by Intelligent Eyewear launch investments, higher capital expenditures, and the timing of partner reimbursements. new
- − Active-customer growth moderated to 3% as the company lapped its highest quarterly growth last year. new
- − The 2026 Intelligent Eyewear contribution is limited by the mid-December delivery start, and guidance includes related launch and operating expenses. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active Customers | 2.71M | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $32.9M | Q2 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 13.1% | Six Months Ended June 30, 2026 | — |
| Average Revenue per Customer | $336 | Q2 2026 | — |
| Free Cash Flow non-GAAP | $6.8M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 29.62M
-22.86M Purchases of property and equipment
= Free Cash Flow 6.76M
|
|||
| Net new stores opened | 15 | Q2 2026 | — |
| Operating cash flow | $29.6M | Q2 2026 | — |
| Store count | 352 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WRBY
this stock
Warby Parker Inc.
|
$3.51B | +29.5% | +13.0% | 469.6 | 16.1% |
|
ISRG
Intuitive Surgical Inc
|
$145.92B | -25.7% | +20.5% | 51.0 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.86B | — | +8.2% | 95.6 | 3.0% |
|
MDLN
Medline Inc.
|
$51.51B | -6.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$36.15B | -4.5% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WRBY | -6.4% | +10.1% | +15.1% | +14.7% | +29.5% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -2.5% | +15.7% | +18.6% | +18.1% | +22.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.